# A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade Glioma

> **NCT07710690** · PHASE1 · RECRUITING · sponsor: **Neuregen Therapeutics Co., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- HGG
- High Grade Glioma (III or IV)
- High Grade Glioma

## Interventions

- **DRUG:** NRG-103

## Key facts

- **NCT ID:** NCT07710690
- **Lead sponsor:** Neuregen Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-09
- **Primary completion:** 2030-04-30
- **Final completion:** 2030-04-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07710690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07710690, "A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade Glioma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07710690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*